IMUNON Successfully Closes $9.75 Million Private Placement
With an upfront amount of $3.25 million and the potential for an additional $6.5 million from short-term warrant exercises, IMUNON, Inc. (NASDAQ: IMNN) has successfully finalized a private placement offering. The company, based in Lawrenceville, has been advancing its DNA-mediated immunotherapy program.
Details of the Offering
In a move to strengthen its capital base, IMUNON announced that it has sold a total of 7,222,223 shares of common stock, alongside short-term warrants, at a price of $0.45 per share. This offering aligns with Nasdaq’s at-the-market rules and is designed to attract accredited investors.
Placement Agents and Their Roles
Leading this offering was H.C. Wainwright & Co. while Brookline Capital Markets participated as a co-placement agent. Together, these firms helped facilitate the successful execution of the private placement process.
Purpose of the Proceeds
The aggregate gross proceeds of approximately $3.25 million will be utilized for working capital and supporting various corporate purposes. Furthermore, the short-term warrants, if fully exercised, could bring additional proceeds amounting to approximately $6.5 million, although participation cannot be guaranteed.
Regulatory Insights
This private placement falls under Section 4(a)(2) of the Securities Act of 1933. Consequently, the shares and associated securities will remain unregistered unless a registration statement is filed with the SEC. The intent is clear: bring forth transparency and compliance in offering securities solely to accredited investors.
About IMUNON
IMUNON is on the forefront of biotechnology, specializing in the development of innovative treatments that leverage the body's own mechanisms to fight diseases. Their approach distinguishes them from traditional therapies while focusing on non-viral DNA technology. Their unique modalities include:
TheraPlas
TheraPlas is engineered to deliver cytokines and therapeutic proteins aimed at treating solid tumors, utilizing an immunological approach believed to be effective.
PlaCCine
This modality targets the gene delivery of viral antigens specific to triggering a robust immunological response.
Clinical Advancements
IMUNON’s lead clinical program is IMNN-001, a DNA-based immunotherapy developed specifically for advanced ovarian cancer treatment. It has progressed through several clinical trials, including notable results from a Phase 2 trial. The approach works by prompting the body to produce durable levels of crucial molecules like interleukin-12 at the tumor site.
Additionally, IMUNON has made significant strides with its COVID-19 booster vaccine, IMNN-101, which recently completed its first-in-human study, showcasing the company's commitment to addressing pressing health challenges.
Looking Ahead
As IMUNON continues to explore and develop its technological capabilities, they plan to enhance their offerings through partnerships or direct advancements in plasmid DNA technology. This commitment to innovation is positioned to benefit patients facing difficult to treat conditions, ensuring the company's relevance in the evolving therapeutic landscape.
Frequently Asked Questions
What is the total amount raised by IMUNON in the private placement?
IMUNON raised a total of $9.75 million through a private placement, including $3.25 million upfront and potential additional proceeds from warrants.
What will the funds from the offering be used for?
The net proceeds from the offering will be allocated toward working capital and general corporate purposes.
Who acted as placement agents for IMUNON’s offering?
H.C. Wainwright & Co. served as the exclusive lead placement agent, while Brookline Capital Markets acted as a co-placement agent.
What innovative therapies is IMUNON developing?
IMUNON is advancing DNA-mediated immunotherapy, with modalities like TheraPlas for solid tumors and PlaCCine for viral antigens.
How does IMNN-001 work in treating ovarian cancer?
IMNN-001 is a DNA-based immunotherapy that stimulates the body to produce effective cancer-fighting molecules at the tumor site.
